7月10日，截至港股收盘，恒生指数上涨0.57%，报24028.37点。雍禾医疗（02279.HK）收报2.22港元/ 股，上涨13.27%，成交量318.6万股，成交额699.39万港元，振幅15.82%。 资料显示，雍禾医疗集团有限公司是一家提供一站式毛发医疗服务的医疗集团,自2005年开始,公司一直 专注于毛发医疗服务市场,并构建了以"雍禾医疗"为核心,由专业植发品牌"雍禾植发"、医疗养固品牌"史 云逊"、女性美学植发品牌"雍禾发之初"及医学假发品牌"哈发达"等组成的全产业链品牌矩阵。经过十 多年的发展,截止2023年6月30日,公司已在中国68个城市拥有72家植发医疗机构。利用标准、成熟的医生 培养体系,如今公司已建立一支一千六百余人的专业医疗团队,其中包括三百余名注册医生及一千余名护 士。目前公司已成为中国植发医疗及医疗养固服务市场的重要品牌。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 最近一个月来，雍禾医疗累计涨幅73.45%，今年来累计涨幅117.78%，跑赢恒生指数19.1%的涨幅。 财务数据显示，截至2024年12月31日，雍禾医疗实现营业总收入18 ...

5月9日，截至港股收盘，恒生指数上涨0.4%，报22867.74点。雍禾医疗（02279.HK）收报1.05港元/ 股，上涨9.38%，成交量56.5万股，成交额57.54万港元，振幅11.46%。 最近一个月来，雍禾医疗累计涨幅1.05%，今年来累计涨幅6.67%，跑输恒生指数13.54%的涨幅。 财务数据显示，截至2024年12月31日，雍禾医疗实现营业总收入18.04亿元，同比增长1.53%；归母净利 润-2.26亿元，同比增长58.58%；毛利率60.08%，资产负债率58.65%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.69倍，行业中值0.28倍。雍禾医 疗市盈率-2.06倍，行业排名第90位；其他巨星医疗控股（02393.HK）为0.19倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.87倍、环球医疗（02666.HK）为4.47倍、瑞慈医疗 （01526.HK）为5.7倍。 资料显示，雍禾医疗集团有限公司是一家提供一站式毛发医疗服务的医疗集团,自2005年开始,公司一直 专注于毛发 ...

Core Viewpoint - Yonghe Medical (02279) reported a total revenue of 1.806 billion yuan for the fiscal year 2024, reflecting a year-on-year growth of 1.5%, while the net profit attributable to shareholders was a loss of 226 million yuan, an improvement from a loss of 546 million yuan in the previous year [3] Financial Performance - The company achieved a net cash flow from operating activities of 229 million yuan, compared to a negative 17.15 million yuan in the same period last year [3] - Basic earnings per share were reported at -0.45 yuan, with a weighted average return on equity of -26.99% [3][25] - As of April 29, the price-to-book ratio (TTM) was approximately 0.67 times, and the price-to-sales ratio (TTM) was about 0.26 times [3] Revenue Composition - In 2024, the revenue composition included 1.3307 billion yuan from hair transplant medical services and 445.8 million yuan from medical hair care services [20] - The company operates a full industry chain brand matrix centered around "Yonghe Medical," including specialized brands for hair transplant and medical hair care [13] Cash Flow and Financing - The net cash flow from financing activities was -291 million yuan, a decrease of 106 million yuan year-on-year, while the net cash flow from investment activities was -53.26 million yuan, compared to 246 million yuan in the previous year [29] Asset and Liability Changes - As of the end of 2024, the company's right-of-use assets decreased by 37.93%, while cash and cash equivalents decreased by 18.27% [37] - The company's lease liabilities decreased by 39.62%, and short-term borrowings decreased by 67.25% [40] - The current ratio was reported at 1.15, and the quick ratio was 1.08 [43]

近日，毛发医疗服务头部企业雍禾医疗披露2024年业绩报告，报告期内实现营收18.05亿元，同比增长 1.5%；EBITDA（除利息、税项、折旧及摊销前）盈利1.41亿元，比上一年度大幅改善。 2022年以来，雍禾医疗进入自我调整变革期，去销售化、去包装化，打破过去的固有模式。应对变革期 带来的"阵痛"，雍禾医疗创始人、董事长兼CEO张玉表示，雍禾医疗快速奔跑了17年，从2022年开始注 重"内修"，进行体系化的搭建，重塑商业模式，正是为了考虑企业未来五年、十年甚至更长远的发展。 放缓脚步，革新成效初现 2021年，受新冠疫情影响，雍禾医疗全国60家门店，最高曾临时关闭30多家。"什么时候能开店不知 道，所以我们就在不确定中干了确定的事，大刀阔斧地改革。我坚信民营医疗未来肯定会很好，但打铁 需要自身硬，对于企业而言，长期主义非常重要，要以患者为中心，为社会真正创造价值。"张玉说 道。 在过去的三年里，雍禾医疗的自我革新首先是去销售化，砍掉现场销售人员，用医生接诊，同时去技术 包装化，回归医疗本质。通过对医生分级，吸引了大量行业优秀医生加入，既能根据消费者的经济能力 提供不同层级的服务，又能让优秀医生的自身价值被 ...

Group 1 - The core viewpoint of the news is that Yonghe Medical, known as the "first stock in hair transplantation," reported a revenue of RMB 1.805 billion for 2024, reflecting a year-on-year growth of 1.5% compared to 2023 [1] - The net loss for Yonghe Medical narrowed by 58.6% from RMB 550 million in 2023 to RMB 227 million in 2024 [1] - The gross profit for the company reached RMB 1.084 billion, representing an 8.7% increase year-on-year, with a gross margin of 60.1% compared to 56.1% in 2023 [1] Group 2 - Yonghe Medical provides a comprehensive range of hair medical services, including hair transplantation, medical care, routine maintenance, and other supporting services [3] - The total number of patients served by the company exceeded 120,000, with 59,655 patients undergoing hair transplantation, generating RMB 1.33 billion in revenue from hair transplantation services, accounting for 73.7% of total revenue [3] - The hair medical service market in China is experiencing rapid growth, with the market size increasing from RMB 58.29 billion in 2020 to RMB 79.55 billion in 2023, and is projected to reach RMB 116.54 billion by 2028 [3] Group 3 - In 2024, Yonghe Medical optimized its number of hair transplant clinics from 75 to 66 and reduced the number of independent stores from 13 to 8 [3] - The company explained that the optimization of the store network involved strategically closing and consolidating inefficient stores, reallocating resources to core locations, which significantly improved operational efficiency [3] - This strategic move not only enhanced the overall robustness of the business but also ensured effective resource utilization, further solidifying the company's competitive advantage in the market [3]